Exosome Dx Presents Data on New Combined Exosomal RNA and ctDNA Liquid Biopsy Platform | GenomeWeb

NEW YORK (GenomeWeb) — Exosome Diagnostics presented data last week on a new platform it has developed to simultaneously isolate and analyze circulating exosomal RNA and cell-free tumor DNA.

According to the company, the combined platform, called EXO52, had a higher cancer mutation detection rate compared to analysis using only cell-free DNA in samples representing multiple cancer types.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.